Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback

Source Summary

Novo Nordisk (CSE: NOVOb, NYSE: NVO) raised its full-year 2025 guidance after stronger-than-expected demand for its blockbuster weight-loss drugs helped improve its earnings outlook. The Danish pharmaceutical company now...